Description

Title of Invention

Composition for treating pain

Technical Field

The present invention relates to a composition for relieving or treating pain, the composition comprising a gene encoding glutamate decarboxylase and a gene encoding an anti-inflammatory cytokine and, in particular, use of the composition in the manufacture of a medicament for relieving or treating pain.

Background Art

The term “pain” used by the International Association for the Study of Pain is defined as “actual or potential tissue damage or an unpleasant sensory and emotional experience associated therewith.” Pain protects parts of the damaged body during the healing of the damage from the damage occurrence and motivates a human being to avoid similar experiences in the future. Most pain is relieved gradually if the cause of stimulus is removed, but sometimes the pain persists even though the damaged site has clearly healed as the stimulus has disappeared, or the pain develops in a state where no irritation, damage or disease has occurred.

Neuropathic pain is a type of non-malignant chronic pain that is induced by abnormality of a nerve, a spinal cord or a brain and is assumed that 1% or more of the population is suffering therefrom. The most common causes of neuropathic pain are trauma, metabolic and ischemic disorders, etc., which cause pathological nerve impulses to be transmitted to the brain through the spinal cord, resulting in pain occurrence. Neuropathic pain can be classified into peripheral neuropathic pain and central neuropathic pain depending on the location affected.

If such neuropathic pain persists for a long period of time, it may lead to mental

pain as well as physical pain, and thus, the life quality of a patient is likely to decline. Therefore, active treatment for pain relief should be carried out. Currently, as the pain itself is recognized as a disease and interests in pain is spreading, demand for analgesics is expected to increase steadily in the future. Mainly, analgesics such as acetylsalicylic acid, ibuprofen, and acetaminophen are widely used in current pain treatments. If aspirin, whose main ingredient is acetylsalicylic acid, is used for analgesic purposes, a high dose of at least 500 mg should be administered. However, since aspirin is a non-steroidal anti-inflammatory analgesic (NSAIDs) and interferes with the production of gastric mucosa by blocking the enzyme (COX-1) that promotes the production of prostaglandin which plays a role in protecting gastric mucosa, the stomach can be easily damaged by gastric acid and gastrointestinal bleeding can easily occur. Further, since aspirin prevents thrombus formation, it can cause bleeding. Ibuprofen is also a non-steroidal anti-inflammatory analgesic ingredient, and therefore, it can cause gastric disturbances as well. In case of analgesics whose main ingredient is acetaminophen such as Tylenol, since acetaminophen is metabolized mostly in the liver, the liver may be damaged. Therefore, there are safety issues to lower its maximum dose, etc. In addition, long-term use of the above-mentioned analgesics often lead to resistance and loss of efficacies even if they are efficacious in the early stage, and specifically in case of neuropathic pain, there is a problem that the nonsteroidal anti-inflammatory agent is not effective even in the maximum dose for each patient, and thus high-dose administration for short term is prescribed. Therefore, the development of a new analgesic for neuropathic pain which exhibits excellent analgesic efficacy at low dose without side effects is urgently required.

Currently, several new substances are being developed as analgesics for neuropathic pain. Recently, sodium channel blockers have been developed, but they are mostly in the form of small molecules and have low selectivity to certain isoforms. Further, they show side effects such as cardio-toxicity, motor impairment, etc., and thus, more research in the future is necessary. As for a gene therapeutic agent, Periphagen

Holdings Inc. has developed a therapeutic agent in which a gene encoding enkephalin, an opioid peptide, was introduced into herpes simplex virus (HSV) gene carrier. However, in a clinical trial, the problem of declining in its analgesic efficacy has been found, and thus, its progression was halted at phase 2 study. HSV had the advantage of delivering genes to peripheral nerves even when subcutaneously administered, but, in fact, gene delivery efficiency is inferior and it seems to have difficulty in suppressing pain with only enkephalin, an opioid peptide.

Disclosure of Invention

The invention is defined in the independent claims. Some optional features of the invention are defined in the dependent claims. An example as disclosed herein relates to use of a composition in the manufacture of a medicament for relieving or treating pain, which composition comprises a gene encoding glutamate decarboxylase (GAD) and a gene encoding an anti-inflammatory cytokine, in particular a gene encoding interleukin-10 (IL-10).

An additional example relates to a composition comprising a gene encoding GAD and a gene encoding an anti-inflammatory cytokine, in particular IL-10, for use in the relief or treatment of pain.

Also disclosed herein is a pharmaceutical composition for relieving or treating pain, which comprises a gene encoding glutamate decarboxylase (GAD) and a gene encoding an anti-inflammatory cytokine, in particular IL-10; and the pharmaceutical composition for use in the relief or treatment of pain.

Advantageous Effects

A pharmaceutical composition as disclosed herein can exhibit analgesic effect with only a small amount of gene delivery, and the pain-relieving efficacy can be observed even with a smaller amount of gene delivery as compared to single administration. GABA, a product of the GAD gene, has the efficacy of blocking pain

signal transduction, but excessive amount of it can cause symptoms such as itching, dizziness, drowsiness, etc., as well as side effects such as increased heartbeat rate or respiration rate. IL-10 is known to be a cytokine that exhibits anti-inflammatory effect, but side effects such as reducing RBC level, etc., were observed when high dose was used systemically. On the other hand, a pharmaceutical composition as disclosed herein can exhibit excellent analgesic efficacy even with a smaller dose by employing co-administration the combination of GAD and IL-10 as compared to single administration, and thus, it shows the synergistic efficacy of lowering conventional side effects and toxicity by low dose administration.

Brief Description of Drawings

Fig. 1 shows a vector map of the plasmid pAAV-hGAD65 used for the production of recombinant adeno-associated viruses.

Fig. 2 shows a vector map of the plasmid pAAV-rIL-10 used for the production of recombinant adeno-associated viruses.

Fig. 3 shows a vector map of the plasmid pAAV-rIL-4 used for the production of recombinant adeno-associated viruses.

Fig. 4 is a diagram confirming the expression level of each protein by Western blot, where adeno-associated viruses respectively introduced with GAD65, IL-10 and IL-4 genes were prepared, and then 293T cells, a human embryonic kidney cell line, were treated with the viruses, and cells or culture media were collected after 48 hours.

Fig. 5 illustrates the expression of GABA by a recombinant adeno-associated virus AAV-hGAD65, which is a diagram showing GABA levels in the media measured by ELISA, where 293T cells, a human embryonic kidney cell line, were treated with AAB-GAD65, and the culture media were collected after 48 hours. Two identical samples were prepared separately for each experiment group, and the bar represents the value for each sample.

Fig. 6 shows the results of comparing the efficacies of co-administration of AAV-

GAD65 and AAV-IL-10 with gabapentin administration, which is a graph confirming the difference in synergistic efficacies of co-administration of AAV-GAD65 and AAV-IL-10 as compared to gabapentin used as a neuropathic pain reliever in the market.

Fig. 7 illustrates efficacies of AAV-GAD65 and AAV-IL-10 depending on combination composition ratios thereof. Particularly, it is a graph showing the synergistic effects in animal behavior analysis with the combination composition ratios of AAV-IL-10 to AAV-GAD of 1: 1, 1: 5, 1: 30.

Fig. 8 is a graph showing the synergistic effects when AAV-GAD65 and AAV-IL-10 were co-administered at 1: 10 and 1: 30 by transforaminal epidural injection.

Fig. 9 shows the results of comparing the efficacies of AAV-GAD65 and AAV-IL-10 with AAV-GAD65 and AAV-IL-4, which illustrates the synergistic effects in animal behavior analysis when IL-10 and IL-4 were respectively combined with GAD65 for use.

Detailed Description

In one disclosed technique, a gene encoding GAD and a gene encoding an anti-inflammatory cytokine are provided in a form of being contained in a carrier, and the carrier includes viral vectors and non-viral vectors such as a plasmid, liposome, or the like.

The gene encoding GAD may be operably contained in a first vector, and the gene encoding an anti-inflammatory cytokine may be operably contained in a second vector.

The viral vector may be at least one selected from the group consisting of adenovirus, adeno-associated virus, herpes simplex virus, lentivirus, retrovirus and poxvirus.

A carrier containing a gene encoding GAD (e.g., a first vector) and a carrier containing a gene encoding an anti-inflammatory cytokine

(e.g., a second vector) may have a virus titer-based mixing ratio per unit volume of 1: 1 to 1: 100, 1: 1 to 1: 80, 1: 1 to 1: 60, 1: 1 to 1: 40, 1: 1 to 1: 20, 1: 1 to 1: 10, 1: 3 to 1: 100, 1: 3 to 1: 80, 1: 3 to 1: 60, 1: 3 to 1: 40, 1: 3 to 1: 20, or 1: 3 to 1: 10, more preferably 1: 1 to 1: 50, and most preferably 1: 5 to 1: 30.

A pharmaceutical composition as disclosed herein can exhibit analgesic effect with only a small amount of genes or carriers containing the same. The composition consists of a vector containing a gene encoding GAD and a vector containing an anti-inflammatory action gene in neural tissues, and the pain-relieving or treating efficacy can be achieved with a smaller amount as compared to single administration by co-administering substances having different analgesic mechanisms. Accordingly, since a composition uses a small amount of genes or carriers containing the same, synergy of superior analgesic efficacies is shown while lowering toxicity.

According to an example, the first vector and the second vector may be adeno-associated viruses. The adeno-associated virus is not limited to a specific serotype, and preferably, it may be any one of AAV1 to AAV5.

GAD may be an enzyme which decarboxylates glutamate to produce GABA (gamma-aminobutyric acid). The gene encoding GAD may be one of GAD65 and GAD67, which are two isoforms. The GAD65 may be a human or rat protein or a gene encoding the same, and specific example thereof may consist of the amino acid sequence of SEQ ID NO: 1 of NCBI accession no. NM_000818, and also may consist of the base sequence of SEQ ID NO: 2 or SEQ ID NO: 3. The GAD67 may be a human or rat protein or a gene encoding the same, and specific example thereof may consist of the amino acid sequence of SEQ ID NO: 4 of NCBI accession no. NM_000817, and also may consist of the base sequence of SEQ ID NO: 5.

In a pharmaceutical composition as disclosed herein, the inflammatory cytokine may be interleukin-10 (IL-10), and synergistic pain-relieving

efficacy is exhibited by co-administration of IL-10 and GAD65.

The IL-10 is one of anti-inflammatory cytokines and is also known as a cytokine synthesis inhibitory factor (CSIF). IL-10 belongs to the class II cytokine and is a homodimer consisting of two subunits of 178 amino acids in length. IL-10 serves the function of inhibiting the activity of NK (natural killer) cells in an immune response, and is involved in signal transduction by forming a complex with the IL-10 receptor. IL-10 may be a human or rat protein or a gene encoding the same, and specific example thereof may consist of the amino acid sequence of SEQ ID NO: 6 of NCBI accession no. NM_012854 or SEQ ID NO: 9 of NCBI accession no. NM_000572, and also may consist of the base sequence of SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 10.

The base sequences of the gene encoding GAD and/or the gene encoding IL-10 of may include mutants thereof, which may be base sequences modified by codon optimization for rats or humans. Specifically, the base sequences having sequence homology of at least 60%, preferably 70% or more, more preferably 80% or more, even more preferably 90% or more, most preferably 95% or more are included, where the “sequence homology %” is identified by comparing two optimally arranged sequences and comparison regions, and a part of the sequences in the comparison region may include addition or deletion (i.e., gap) as compared to a reference sequence (not including addition or deletion) regarding the optimal arrangements of the two sequences.

The present techniques may also provide the pharmaceutical composition for use in the relief and/or treatment of pain. A therapeutically effective amount of the pharmaceutical composition may be administered to a patient in need of relieving and/or treating pain. Prior to administration, it is typically determined whether the patient is a patient in need of relieving and/or treating pain. The term “therapeutically effective amount” may depend on the amount of an active gradient to achieve a desired efficacy, pain relief and/or therapeutic efficacy.

The pain according may include nociceptive pain, psychogenic pain, inflammatory pain associated with tissue damage and immune cell infiltration, pathological pain which is a disease state induced by damage to the nervous system or its abnormal function (dysfunctional pain such as fibromyalgia, irritable bowel syndrome, tension headache), etc. Also, the pain may include back pain distinguished anatomically, such as: neck pain, middle back pain, lower back pain, or tailbone pain. In addition, the pain may include pain such as neuropathic pain, migraine, etc. Neuropathic pain can result from damage or diseases that affect the somatosensory system. Neuropathic pain may be associated with an abnormal sensation called dysesthesia, and with allodynia in which pain sensation is evoked even with painless stimulation. Also, the neuropathic pain may also be a continuous and/or intermittent (seizure) factor. The latter is linked to electric shock in the figurative sense. General characteristics include being hot or cold, pins and needles, numbness, and itching.

In contrast, nociceptive pain is often expressed as “ache”. In addition, migraine is a chronic disorder that is associated with a number of autonomic nervous system symptoms and causes headaches of ordinary to severe intensities. The precise mechanisms of these migraines have not been clarified yet. The basic theory is related to the increased excitability of the cerebral cortex and the abnormal regulation of pain nerve cells in the trigeminal nucleus of the brainstem.

As a specific example, pain may be at least one selected from the group consisting of neuropathic pain, cancer pain, postoperative pain, trigeminal neuralgia, idiopathic pain, diabetic neuropathic pain, migraine, etc. As another specific example, the pain may not be a muscle spasm associated with lumbago.

Preferably, a composition may be used for relieving or treating neuropathic pain or chronic cancer pain. The term “relieving or treating” refers to any action that alleviates or improves pain symptom by administering a composition as disclosed herein.

An additional example relates to a method for relieving or

treating pain comprising administering a gene encoding GAD and a gene encoding an anti-inflammatory cytokine to a subject in need thereof. The subject may be a mammal including a human, or a cell and/or tissue isolated from a mammal including a human. Also, the subject may be a non-human animal, and the term "non-human animal" includes vertebrates such as mammals and non-mammals, for example, primates except humans, sheep, dogs, cats, horses, cows, chickens, amphibians, reptiles, etc.

The therapeutically effective amount and administration route of a pharmaceutical composition can be appropriately adjusted in consideration of a condition of the patient, a desired efficacy, and the like by those of ordinary skill in the art. For example, a composition may be provided in the form of an injection, and may include, for example, nerve injection, subcutaneous injection, intramuscular injection, or gene gun injection.

Mode for the Invention

Hereinafter, the present invention is explained in detail by Examples, but the following Examples are intended to further illustrate the present invention without limiting its scope.

<Example 1> Preparation and property analysis of recombinant adeno-associated viruses

The adeno-associated viruses required for the present techniques were prepared and produced based on the AAV helper-free system (Agilent, USA).

A. Preparation of pAAV-hGAD65

To prepare pAAV-hGAD65 of Fig. 1, the CMV promoter region of pJDK-rGAD65 [Lee B et al., Gene Ther, 12: 1215-1222 (2005)] was amplified by PCR and then introduced into pGEM-T (Promega, USA), to prepare pGEM-T-CMV. The primer

sequences used for the amplification of CMV promoter are as follows.

F-JDK (SEQ ID NO: 16): 5'-TTCGGCCGTCGAGGAGCTTGGCCCATTG-3'

R-JDK (SEQ ID NO: 17):

5'-GACGTCGACCTAGCTAGCGAATTCGGGGCCGCGGAG-3'

The GAD65 gene was prepared by codon-optimization to fit for humans based on the human GAD65 sequence having the amino acid sequence of SEQ ID NO: 1 (NCBI NM_000818) and synthesizing the base sequence of SEQ ID NO: 3 (Bioneer, Korea). The hGAD65 gene introduced into pGEM-T was treated with NheI and SalI to obtain a 1.7 Kb DNA fragment, which was ligated to a 3.7 Kb DNA fragment obtained by treating pGEM-T-CMV with NheI and SalI, to complete pGEM-T-CMV-hGAD65.

SV40pA was amplified by performing PCR using pCI (Invitrogen, USA) as a template, followed by treatment with ClaI and SalI, to obtain a 222 bp DNA fragment. The above fragment was ligated to a 5.4 Kb DNA fragment prepared by cutting pGEM-T-CMV-hGAD65 with ClaI and SalI, to finally prepare pGEM-T-CMV-hGAD65-SV40pA. The primer sequences used for the amplification of SV40pA are as follows.

F-SV40pA (SEQ ID NO: 18):

5'-CCATCGATCAGACATGATAAGATACATTGATGAG-3'

R-SV40pA (SEQ ID NO: 19):

5'-GACGTCGACGCGGCCGCTACCACATTTGTAGAGGTTTTACTTG -3'

The ampicillin-resistance gene in pAAV-MCS (Agilent, USA) was replaced with kanamycin-resistance gene for the preparation of adeno-associated virus vectors. The kanamycin-resistance gene was amplified by PCR using pET-28(a) (Novagen, USA) as a template, and the amplified 816 bp kanamycin-resistance gene was ligated to pGEM-T, to prepare pGEM-T-Kan^r. The primer sequences used for the amplification of kanamycin-resistance gene are as follows.

F-Kan (SEQ ID NO: 20): 5'-AGGCGCCATGAGCCATATTCAACGGGAA-3'

R-Kan (SEQ ID NO: 21): 5'-TTCATGATTAGAAAAACTCATCGAGCATC-3'

For the introduction of the kanamycin-resistance gene, SpeI and EcoRV sites were

respectively generated at the front and back of the ampicillin-resistance gene in pAAV-MCS by mutagenesis, and treated with SpeI and EcoRV, which was then ligated to the DNA fragment obtained by cutting the pGEM-T-Kan^r prepared above with NheI and EcoRV, to prepare pAAV-MCS-Kan^r.

The prepared pAAV-MCS-Kan^r was treated with NotI and BamHI, which was then ligated to a 2.7 Kb DNA fragment obtained by cutting pGEM-T-CMV-hGAD65-SV40pA with EagI and PvuI, to prepare pssAAV-GAD65.

In order to introduce the GAD65 expression cassette into pVAX1 (Invitrogen, USA), BamHI site was generated at the back of bGHpA by mutagenesis, which was then cut with MluI and NheI, to prepare DNA fragments. The LITR and CMV promoter regions were amplified by PCR using the pssAAV-GAD65 as a template, and cloned into pGEM-T easy (Promega, USA), which were then cut with AscI and NheI, and ligated to the pVAX1 vector prepared above, to prepare pVAX1-LITR-CMV. The primer sequences used for the amplification of LITR and CMV promoter regions are as follows.

F-ITR (SEQ ID NO: 22): 5'-ATGGCGCGCCCCTGGCCTTTTGCTGGCC-3'

R-JDK (SEQ ID NO: 17):

5'-GACGTCGACCTAGCTAGCGAATTCGGGGCCGCGGAG-3'

The pVAX1-LITR-CMV was prepared as a DNA fragment by cutting with NotI and NheI, and ligated to the DNA fragment prepared by cutting the pssAAV-GAD65 with Eagl and Nhel, to prepare pVAX1-LITR-CMV-hGAD65-SV40pA.

The pVAX1-LITR-CMV-hGAD65-SV40pA was cut with HpaI and BamHI, and then ligated to the DNA fragments obtained by treating the pGEM-T easy-SV40pA-RITR, which had been amplified by PCR using pssAAV-GAD65 as a template and cloned into pGEM-T easy, with Hpal and BamHI, to complete pVAX1-LITR-CMV-hGAD65-SV40pA-RITR (hereinafter, abbreviated as “pAAV-GAD65”). The primer sequences used for the amplification of SV40pA and RITR regions are as follows.

F-SV40pA (SEQ ID NO: 18):

5'-CCATCGATCAGACATGATAAGATACATTGATGAG-3'

R-ITR (SEQ ID NO: 23): 5'-ATGGATCCGCTAGTAAATACCGCATCAG-3'

The vector map of pAAV-hGAD65 is shown in Fig. 1.

B. Preparation of pAAV-rIL-10

pAAV-rIL-10 was prepared by a similar method to pAAV-hGAD65. Rat IL-10 gene was prepared by codon-optimization to fit for rats based on rat-derived base sequence (NCBI NM_012854) having the amino acid sequence of SEQ ID NO: 6 and synthesizing a gene having the base sequence of SEQ ID NO: 8 (Bioneer, Korea). The rIL-10 genes were amplified by PCR using the rat IL-10 genes introduced into pGEM-T easy as a template, and then treated with NheI and SalI to obtain a 0.5 Kb DNA fragment, which was then ligated to a 3.7 Kb DNA fragment obtained by cutting the pGEM-T-CMV with NheI and SalI, to prepare pGEM-T-CMV-rIL-10. The primer sequences used for the amplification of rIL10 is as follows.

F-rIL-10 (SEQ ID NO: 24): 5'-CCGCTAGCGCCACCATGCCT-3'

R-rIL-10 (SEQ ID NO: 25):

5'-GACGTCGACGCCATCGATGGCTTAATTAATCAATTCTTC-3'

SV40pA was amplified by performing PCR using pCI as a template, followed by treatment with NotI and SalI to obtain a 222 bp DNA fragment. The above fragment was ligated to a 4.2 Kb DNA fragment prepared by cutting pGEM-T-CMV-rIL-10 prepared above with ClaI and SalI, to prepare pGEM-T-CMV-rIL-10-SV40pA. The primer sequences used for the amplification of SV40pA are as follows.

F-SV40pA (SEQ ID NO: 18):

5'-CCATCGATCAGACATGATAAGATACATTGATGAG-3'

R-SV40pA (SEQ ID NO: 19):

5'-GACGTCGACGCGGCCGCTACCACATTTGTAGAGGTTTTACTTG -3'

A 1.6 Kb DNA fragment was obtained by treating pGEM-T-CMV-rIL-10-SV40pA with EagI, and then ligated to the DNA fragment prepared by treating pAAV-MCS-

Kan^r with NotI and BamHI, to prepare pssAAV-CMV-rIL-10-SV40pA (hereinafter, abbreviated as “pAAV-rIL-10”). The vector map of pAAV-rIL-10 is shown in Fig. 2.

C. Preparation of pAAV-rIL-4

The rat IL-4 gene was prepared by codon-optimization to fit for rats based on the rat-derived base sequence (NCBI NM_201270) having the amino acid sequence of SEQ ID NO: 11 and synthesizing a gene having the base sequence of SEQ ID NO: 13 (Bioneer, Korea). The rIL-4 genes introduced into pGEM-B1 (Bioneer, Korea) were treated with NheI and NotI to obtain a 0.5 Kb DNA fragment. The above fragment was ligated to a 3 Kb DNA fragment prepared by treating pAAV-hGAD65 with NheI and NotI, to prepare pssAAV-CMV-rIL-4-SV40pA (hereinafter, abbreviated as "pAAV-rIL-4"). The vector map of pAAV-rIL-4 is shown in Fig. 3.

D. Property analysis of recombinant adeno-associated viruses

The three types of plasmids (pAAV-hGAD65, pAAV-rIL-10 and pAAV-rIL-4) prepared above were respectively transfected into 293T cells, a human embryonic kidney cell line, with pHelper and pRC using PEI (Polysciences, USA). Herein, pRC5 into which the capsid gene of AAV serotype 5 was introduced was used for hGAD65, while pRC1 into which the capsid gene of AAV serotype 1 was introduced was used for rIL-10 and rIL-4. The transfected cells were cultured in a 37°C incubator, collected after 48 hours, and subjected to 3 cycles of freezing and thawing to obtain each crude virus.

In order to confirm the protein expression of the recombinant adeno-associated viruses delivered to the cells, 293T cells, a human embryonic kidney cell line, were respectively treated with crude viruses AAV5-hGAD65, AAV1-rIL-10 and AAV1-rIL-4, the protein expression was confirmed by Western blot. Specifically, 8 x 10^5 293T cells were aliquoted into T25 flasks, and each flask was treated with 700 μL of crude viruses on the next day, followed by culturing in a 37°C incubator. After 48 hours, the cells and

the culture media were harvested separately, and the cells were dissolved with a solubilizing agent and the culture media were concentrated with amicon (Merck Millipore, Germany). The prepared samples were treated with the antibodies to GAD65 (Cell signaling, USA), IL-10 (Santa Cruz, USA) and IL-4 (Santa Cruz, USA), respectively, and subjected to Western blot. The results are shown in Fig. 4.

Fig. 4 is a diagram showing the expression of each protein by performing Western blot analysis of the cell lysates of 293T cell line, a human embryonic kidney cell line, treated with AAV5-hGAD65, AAV1-rIL-10 or AAV1-rIL-4. By confirming that a target protein was expressed in every case, it was confirmed that there was no problem in the structure and property of the recombinant adeno-associated viruses used in the experiment.

In order to confirm that GABA is produced by AAV5-hGAD65, the culture media of the cells treated with AAV5-GAD65 were collected under the same condition as that for sample preparation for Western blot, and subjected to GABA ELISA (LDN, Netherland) analysis. The results are shown in Fig. 5. Two identical samples were prepared separately for each experiment group, and the bar represents the value for each sample. As a result, it was confirmed that GABA was secreted into the culture medium by GAD65 introduced into the cells by AAV5-hGAD65 viruses.

E. Preparation of recombinant adeno-associated viruses

Recombinant adeno-associated viruses were prepared and purified by KRcrogen (Korea) for animal efficacy experiments, and the preparation method is as follows.

Three types of plasmids (pAAV-hGAD65, pAAV-rIL-10, and pAAV-rIL-4) prepared above were respectively transfected into 293T cells, a human embryonic kidney cell line, using calcium phosphate method with pHelper and pRC. Herein, pRC5 into which the capsid gene of AAV serotype 5 was introduced was used for hGAD65, while pRC1 into which the capsid gene of AAV serotype 1 was introduced was used for rIL-10 and rIL-4. The transfected cells were cultured in a 37°C incubator,

and collected after 48 hours.

Then, only the bands containing viruses were isolated and purified through high-speed centrifugation depending on cesium concentration gradient, to obtain AAV5-hGAD65, AAV1-rIL-10 and AAV1-rIL-4. The titers of the produced viruses were measured using qPCR method established by the manufacturer.

<Example 2> Analgesic efficacy test of AAV-IL-10 and AAV-GAD65

A. Preparation of administration samples

30 minutes before the animal administration, the recombinant adeno-associated virus stored at -80°C were thawed at room temperature within 1 minute and mixed well by vortex. And Coomassie blue dye solution was prepared by mixing 10 mg of Coomassie blue in 1 mL of PBS well, and then filtering by syringe filters. 1 μL of AAV-GAD65 of 5.4 x 10^5 VG/μL, 1 μL of AAV-IL-10 of 1.8 x 10^7 VG/μL and 1 μL of 0.1% Coomassie blue dye were mixed under the calculation that each animal gets 3 μL in total. The samples were prepared twice as much as the amount required, and 3 μL of the sample was administered to each animal.

As a control group, Gabapentin was mixed in animals' drinking water 1 hour prior to administration, which was prepared in a concentration of 10 mg/mL.

B. Preparation of neuropathic pain animal model and sample administration

Male SD-rats of 180 to 200g were anesthetized with inhalation anesthesia, and then upper parts of the calves were incised, and both ends of the common peroneal nerve and tibial nerve were tied and knots were made by 7-0 suture at 0.5-1 cm intervals. The regions of the two nerve bundles between the knots were cut by scissors and the incision site was sutured. Two weeks later, *von Frey* filament test was performed to confirm pain induction, and then the test substance was administered (C.J. Woolf, *Pain* 87, 2000).

The test substance was administered to dorsal root ganglion (DRG). After

inhalation anesthesia of the pain animal model, rat's back at the lumbar spine from L3 to L5 was linearly incised to expose vertebral bones, and then a transverse process, one of the spinal projections, was exposed at the side of the exposure, and the L4 process covering the DRG in the fixed state was carefully separated under the Stereo zoom microscopic view by a rongeur such that the DRG is not damaged. The area around the DRG was manipulated so that the DRG which extends in an oblique line was exposed like grains of rice.

A hamilton syringe was connected to a polyethylene catheter, and 3 μL of the test substance was accurately collected. Then, the syringe was replaced with a 1 mL syringe for the administration. The rats were placed on a small animal stereotaxic instrument, and the sample was injected while confirming that the micro-needle was pricking the L4 DRG accurately under a surgioscope. Herein, it was confirmed that the sample containing dye did not leak out of the DRG and was well delivered to the inside of the DRG. After confirming that entire sample was delivered to the DRG, the syringe was separated from the DRG, and suturing was done, and the animals were recovered.

Gabapentin was orally administered with 3 mg/kg.

C. Observation of analgesic efficacy using *von Frey* filament test

The 50% up & down threshold method established by Dixon in 1992 was employed since it is a commonly known method. The method calculates threshold values depending on a predetermined patterns of pain responses with a total of 8 filaments whose N values were 0.4, 0.6, 1, 2, 4, 6, 8 and 15 g, respectively. Pain occurrence regions were searched through changing positions from the region of most lateral toe to the heel of the sole where pain has occurred.

Rats abruptly lift the soles and shrink or lick the soles when pain occurs. Accordingly, when pain occurring region was found, the surrounding area was pricked 5 times with the filament of the next step and if there were responses for 3 times or more, it was regarded as a pain response, and the rats were observed with the filament

of the next step. Patterns were recorded at every step. The pain patterns were recorded based on the pattern table established by S.R. Chaplan (Quantitative assessment of tactile allodynia in the rat paw. *Journal of Neuroscience Methods*, 1994) and the threshold values were calculated using it. The behavior analysis of the animal groups is performed by a blind method for 4 to 6 weeks, observed by at least 3 people, and the results of the recorded patterns are statistically processed to analyze the tendency of pain.

The results of pain-observation employing *von Frey* filament test where the pain animal model was administered with samples are shown in Fig. 6. Fig. 6 shows the results of comparing the efficacies between co-administration of AAV-GAD65 and AAV-IL-10 and gabapentin administration. When GAD65 and IL-10 were co-administered, statistically significant pain-relieving effect was observed as compared to the untreated control group (negative control), and the effect was found to be higher than that of Gabapentin.

<Example 3> Analgesic efficacy tests of AAV-IL-10 and AAV-GAD65

A. Preparation of administration samples

For the preparation of administration samples, rAAV5-GAD65 and rAAV1-rIL-10 which were prepared in Example 1 and stored in a frozen state were thawed, and samples were prepared in accordance with substantially the same method as the preparation method of administration samples in Example 2. Specifically, the single administration substance AAV-GAD65 or AAV-rIL-10 and the co-administration substances AAV-GAD65 and AAV-rIL-10 were diluted in PBS in a virus titer-based mixing ratio of 1:1, 1:5, or 1:30 as shown in Table 1, and 1 μL of 0.1% Coomassie blue dye was added to each sample under the calculation that each animal gets 3 μL. The samples were prepared twice as much as the amount required for the total population, and 3 μL of the sample was administered to each animal.

[Table 1]

Samples	Virus types and contents	
	AAV-GAD65	AAV-IL-10
Comparative Example 1 (GAD alone)	5.4×10^5 VG/ 2 μL	0
Comparative Example 2 (IL-10 alone)	0	1.8×10^7 VG/ 2 μL
Experimental Example 1 (1:1)	5.4×10^5 VG/ 1 μL	5.4×10^5 VG/ 1 μL
Experimental Example 2 (1:5)	5.4×10^5 VG/ 1 μL	2.7×10^6 VG/ 1 μL
Experimental Example 3 (1:30)	5.4×10^5 VG/ 1 μL	1.8×10^7 VG/ 1 μL

B. Observation of analgesic efficacy using *von Frey* filament test

Samples were administered to the pain animal models prepared by the same method as in Example 2, and pain was observed using a *von Frey* filament test, and the results are shown in Fig. 7.

Fig. 7 illustrates efficacies of AAV-GAD65 and AAV-IL-10 depending on composition ratios thereof. Particularly, compared to trace amounts of AAV-GAD65 and AAV-rIL-10 which showed no analgesic efficacy experiments with the mixing composition ratios of AAV-rIL-10 to AAV-GAD of 1:1 (Experimental Example 1), 1:5 (Experimental Example 2) and 1:30 (Experimental Example 3) exhibited synergistic efficacies in animal behavior analysis. As a result, the co-administration composition of AAV-GAD65 and AAV-rIL-10 showed an increasing pattern of the pain treatment efficacy as the mixing composition ratio of AAV-rIL-10 to AAV-GAD increased.

<Example 4> Analgesic efficacy tests of AAV-IL-10 and AAV-GAD65 using transforaminal epidural injection

A. Preparation of administration samples

30 minutes before the animal administration experiment, the reagents kept at -80°C were thawed at room temperature within 1 minute and mixed well by vortex. AAV-GAD65 and AAV-IL-10 were diluted in PBS to obtain the viral titers shown in Table 2. In order to administer 5 μL of the sample to each animal, the two virus diluted solutions were mixed half and half to obtain 1.5 times the volume required. Then, 5 μL of the sample was administered to each animal.

[Table 2]

Samples	Virus types and contents	
	AAV-GAD65	AAV-IL-10
Experimental Example1 (1: 10)	5.0×10^6 VG/ 2.5 μL	5.0×10^7 VG/ 2.5 μL
Experimental Example2 (1: 30)	5.0×10^6 VG/ 2.5 μL	1.5×10^8 VG/ 2.5 μL

B. Preparation of neuropathic pain model and sample administration

The neuropathic pain animal model was prepared by the same method as described in Example 2, and then the test substance was administered.

The test substance was administered by transforaminal epidural injection method at a position adjacent to the dorsal root ganglion (DRG). After inhalation anesthesia of the neuropathic pain animal model, rat's back at the lumbar spine from L3 to L5 was linearly incised to expose vertebral bones, and then, L4 transverse process, one of the spinal projections, was exposed at the side of the exposure. The rat was laid down sideways such that its side aspect could be seen from above, so that the L4 intervertebral foramen is visible.

A micro needle attached to the catheter was put into the prepared sample. A Hamilton syringe was connected to the opposite end of the catheter and pulled until reaching the marking of 5 μL to inject the sample into the catheter. After removing the

Hamilton syringe from the catheter, the region at 1 cm from the tip of the needle was gripped by Halsted-Mosquito. As L4 spine was gripped by forceps and pulled upward, the tip area of the needle fixed by Halsted-Mosquito Straight was placed around the L4 intervertebral foramen. The tip of the needle was inserted into the intervertebral foramen whose space was secured, and advanced until the needle reached a bent portion inside the intervertebral foramen, and the needle which had been gripped was released. After confirming that the needle is fixed, a 1 mL syringe was connected to the polyethylene catheter connected to the opposite side of the needle. The piston was gently pressed to slowly administer the diluted administration substance to the rat DRG surrounding area, followed by suturing, to complete the administration procedure. By the same method as described in Example 2, pain results employing the *von Frey* filament test were observed at 4 weeks after administration of the substance. The results are shown in Fig. 8.

Figure 8 shows that a mixture of AAV-GAD65 and AAV-IL-10 exhibits efficacy even when administered by the transforaminal epidural injection method. In addition, synergistic efficacy in animal behavior analysis was confirmed at the mixed composition ratio of AAV-GAD65 to AAV-IL-10 of 1: 10 (Experimental Example 1) and 1: 30 (Experimental Example 2).

<Example 5> Comparison of efficacies of AAV-GAD65 and AAV-IL-10 with AAV-GAD65 and AAV-IL-4

A pain animal model was prepared by substantially the same method as in Example 2, and the preparation procedure of the administration sample was the same as well. AAV1-rIL-4 described in Example 1 was thawed and prepared for use in animal experiments as follows.

30 minutes before animal DRG administration experiment, the reagents stored at -80°C were thawed at room temperature within 1 minute and mixed well by vortex. 10 mg of Coomassie blue was mixed well in 1 mL of PBS, and then, dyes filtered by

syringe filters were prepared. AAV-GAD65 and AAV-rIL-4 were diluted in PBS to obtain the virus titer-based mixing ratios shown in Table 3, and 1 μL of 0.1% Coomassie blue dye was added to each sample under the calculation that each animal gets 3 μL. The samples were prepared twice as much as the amount required for the total population, and 3 μL of the sample was administered to each animal.

[Table 3]

Samples	Virus types and contents		
	AAV-GAD65	AAV-IL-10	AAV-IL-4
Comparative Example 1	5.4×10^5 VG/ 2 μL	-	-
Comparative Example 2	-	1.8×10^7 VG/ 2 μL	-
Comparative Example 3	-	-	1.8×10^7 VG/ 2 μL
Comparative Example 4	5.4×10^5 VG/ 1 μL	-	1.8×10^7 VG/ 1 μL
Experimental Example 1	5.4×10^5 VG/ 1 μL	1.8×10^7 VG/ 1 μL	-

The pain results employing the *von Frey* filament test were observed, and the results are shown in Fig. 9. The Fig. 9 shows the results of comparing the efficacies of AAV-GAD65 and AAV-rIL-10 with AAV-GAD65 and AAV-rIL-4, which illustrates the synergistic efficacies comparatively appearing in animal behavior analysis when IL-10 and IL-4, cytokines having anti-inflammatory effects, were used in combination with GAD65, respectively. As shown in Fig. 9, the pain treatment efficacy was insignificant or not observed when GAD65, IL-10 or IL-4 was administered alone, and no significant analgesic efficacy was observed when GAD65 and IL-4 were co-administered as compared to the cases where GAD65 or IL-4 was administered alone. On the other hand, when GAD65 and IL-10 were co-administered, it was confirmed

that there was higher analgesic efficacy which was statistically significant than the other comparative examples. In particular, synergistic pain-relieving effect was observed, which was not shown when GAD65 and IL-4 were co-administered.

PCT/KR 2016. / 0 1 0 4 8 0

<110> KOLON LIFE SCIENCE, INC.

<120> Composition for treating pain

<130> OPP20162511KR

<160> 25

<170> KopatentIn 2.0

<210> 1
<211> 585
<212> PRT
<213> Homo sapiens

<400> 1

```
Met Ala Ser Pro Gly Ser Gly Phe Trp Ser Phe Gly Ser Glu Asp Gly
 1               5                  10                  15

Ser Gly Asp Ser Glu Asn Pro Gly Thr Ala Arg Ala Trp Cys Gln Val
            20                  25                  30

Ala Gln Lys Phe Thr Gly Gly Ile Gly Asn Lys Leu Cys Ala Leu Leu
        35                  40                  45

Tyr Gly Asp Ala Glu Lys Pro Ala Glu Ser Gly Gly Ser Gln Pro Pro
    50                  55                  60

Arg Ala Ala Ala Arg Lys Ala Ala Cys Ala Cys Asp Gln Lys Pro Cys
65                  70                  75                  80

Ser Cys Ser Lys Val Asp Val Asn Tyr Ala Phe Leu His Ala Thr Asp
                85                  90                  95

Leu Leu Pro Ala Cys Asp Gly Glu Arg Pro Thr Leu Ala Phe Leu Gln
            100                 105                 110

Asp Val Met Asn Ile Leu Leu Gln Tyr Val Val Lys Ser Phe Asp Arg
        115                 120                 125

Ser Thr Lys Val Ile Asp Phe His Tyr Pro Asn Glu Leu Leu Gln Glu
    130                 135                 140

Tyr Asn Trp Glu Leu Ala Asp Gln Pro Gln Asn Leu Glu Glu Ile Leu
145                 150                 155                 160

Met His Cys Gln Thr Thr Leu Lys Tyr Ala Ile Lys Thr Gly His Pro
                165                 170                 175

Arg Tyr Phe Asn Gln Leu Ser Thr Gly Leu Asp Met Val Gly Leu Ala
            180                 185                 190
```

Ala Asp Trp Leu Thr Ser Thr Ala Asn Thr Asn Met Phe Thr Tyr Glu
195 200 205

Ile Ala Pro Val Phe Val Leu Leu Glu Tyr Val Thr Leu Lys Lys Met
210 215 220

Arg Glu Ile Ile Gly Trp Pro Gly Gly Ser Gly Asp Gly Ile Phe Ser
225 230 235 240

Pro Gly Gly Ala Ile Ser Asn Met Tyr Ala Met Met Ile Ala Arg Phe
245 250 255

Lys Met Phe Pro Glu Val Lys Glu Lys Gly Met Ala Ala Leu Pro Arg
260 265 270

Leu Ile Ala Phe Thr Ser Glu His Ser His Phe Ser Leu Lys Lys Gly
275 280 285

Ala Ala Ala Leu Gly Ile Gly Thr Asp Ser Val Ile Leu Ile Lys Cys
290 295 300

Asp Glu Arg Gly Lys Met Ile Pro Ser Asp Leu Glu Arg Arg Ile Leu
305 310 315 320

Glu Ala Lys Gln Lys Gly Phe Val Pro Phe Leu Val Ser Ala Thr Ala
325 330 335

Gly Thr Thr Val Tyr Gly Ala Phe Asp Pro Leu Leu Ala Val Ala Asp
340 345 350

Ile Cys Lys Lys Tyr Lys Ile Trp Met His Val Asp Ala Ala Trp Gly
355 360 365

Gly Gly Leu Leu Met Ser Arg Lys His Lys Trp Lys Leu Ser Gly Val
370 375 380

Glu Arg Ala Asn Ser Val Thr Trp Asn Pro His Lys Met Met Gly Val
385 390 395 400

Pro Leu Gln Cys Ser Ala Leu Leu Val Arg Glu Glu Gly Leu Met Gln
405 410 415

Asn Cys Asn Gln Met His Ala Ser Tyr Leu Phe Gln Gln Asp Lys His
420 425 430

Tyr Asp Leu Ser Tyr Asp Thr Gly Asp Lys Ala Leu Gln Cys Gly Arg
435 440 445

His Val Asp Val Phe Lys Leu Trp Leu Met Trp Arg Ala Lys Gly Thr
450 455 460

Thr Gly Phe Glu Ala His Val Asp Lys Cys Leu Glu Leu Ala Glu Tyr

465 470 475 480

Leu Tyr Asn Ile Ile Lys Asn Arg Glu Gly Tyr Glu Met Val Phe Asp
485 490 495

Gly Lys Pro Gln His Thr Asn Val Cys Phe Trp Tyr Ile Pro Pro Ser
500 505 510

Leu Arg Thr Leu Glu Asp Asn Glu Glu Arg Met Ser Arg Leu Ser Lys
515 520 525

Val Ala Pro Val Ile Lys Ala Arg Met Met Glu Tyr Gly Thr Thr Met
530 535 540

Val Ser Tyr Gln Pro Leu Gly Asp Lys Val Asn Phe Phe Arg Met Val
545 550 555 560

Ile Ser Asn Pro Ala Ala Thr His Gln Asp Ile Asp Phe Leu Ile Glu
565 570 575

Glu Ile Glu Arg Leu Gly Gln Asp Leu
580 585

<210> 2
<211> 2824
<212> DNA
<213> Homo sapiens

<400> 2
gcggccgccc gcacttcccg cctctggctc gcccgaggac gcgctggcac gcctcccacc 60

ccctcactct gactccagct ggcgtgcatg gtctgcctcg catcctcacg actcagctcc 120

ctccctctct cgtgtttttt tcctccgccg ccccctcatt catccccact gggctccctt 180

tccctcaaat gctctggggc tctccgcgct ttcctgagtc cgggctccga ggacccttag 240

gtagtcccgg tctcttttaa agctccccgg cttccaaagg gttgccacgt ccctaaaccc 300

tgtctccagc tcgcatacac acacgcacag acacgcacgt tttctgttcc tgcgtgacac 360

ccgccctcgc cgctcggccc cgccggtccc cgcgcggtgc cctcctcccg ccacacgggc 420

acgcacgcgc gcgcagggcc aagcccgagg cagctcgccc gcagctcgca ctcgcaggcg 480

acctgctcca gtctccaaag ccgatggcat ctccgggctc tggcttttgg tctttcgggt 540

cggaagatgg ctctggggat tccgagaatc ccggcacagc gcgagcctgg tgccaagtgg 600

ctcagaagtt cacgggcggc atcggaaaca aactgtgcgc cctgctctac ggagacgccg 660

agaagccggc ggagagcggc gggagccaac ccccgcgggc cgccgcccgg aaggccgcct 720

gcgcctgcga ccagaagccc tgcagctgct ccaaagtgga tgtcaactac gcgtttctcc 780

atgcaacaga cctgctgccg gcgtgtgatg gagaaaggcc cactttggcg tttctgcaag 840

atgttatgaa cattttactt cagtatgtgg tgaaaagttt cgatagatca accaaagtga 900

ttgatttcca ttatcctaat gagcttctcc aagaatataa ttgggaattg gcagaccaac 960

cacaaaattt ggaggaaatt ttgatgcatt gccaaacaac tctaaaatat gcaattaaaa 1020

cagggcatcc tagatacttc aatcaacttt ctactggttt ggatatggtt ggattagcag 1080

cagactggct gacatcaaca gcaaatacta acatgttcac ctatgaaatt gctccagtat 1140

ttgtgctttt ggaatatgtc acactaaaga aaatgagaga aatcattggc tggccagggg 1200

gctctggcga tgggatattt tctcccggtg gcgccatatc taacatgtat gccatgatga 1260

tcgcacgctt taagatgttc ccagaagtca aggagaaagg aatggctgct cttcccaggc 1320

tcattgcctt cacgtctgaa catagtcatt tttctctcaa gaagggagct gcagccttag 1380

ggattggaac agacagcgtg attctgatta aatgtgatga gagagggaaa atgattccat 1440

ctgatcttga aagaaggatt cttgaagcca aacagaaagg gtttgttcct ttcctcgtga 1500

gtgccacagc tggaaccacc gtgtacggag catttgaccc cctcttagct gtcgctgaca 1560

tttgcaaaaa gtataagatc tggatgcatg tggatgcagc ttggggtggg ggattactga 1620

tgtcccgaaa acacaagtgg aaactgagtg gcgtggagag ggccaactct gtgacgtgga 1680

atccacacaa gatgatggga gtccctttgc agtgctctgc tctcctggtt agagaagagg 1740

gattgatgca gaattgcaac caaatgcatg cctcctacct ctttcagcaa gataaacatt 1800

atgacctgtc ctatgacact ggagacaagg ccttacagtg cggacgccac gttgatgttt 1860

ttaaactatg gctgatgtgg agggcaaagg ggactaccgg gtttgaagcg catgttgata 1920

aatgtttgga gttggcagag tatttataca acatcataaa aaaccgagaa ggatatgaga 1980

tggtgtttga tgggaagcct cagcacacaa atgtctgctt ctggtacatt cctccaagct 2040

tgcgtactct ggaagacaat gaagagagaa tgagtcgcct ctcgaaggtg gctccagtga 2100

ttaaagccag aatgatggag tatggaacca caatggtcag ctaccaaccc ttgggagaca 2160

aggtcaattt cttccgcatg gtcatctcaa acccagcggc aactcaccaa gacattgact 2220

tcctgattga agaaatagaa cgccttggac aagatttata ataaccttgc tcaccaagct 2280

gttccacttc tctagagaac atgccctcag ctaagccccc tactgagaaa cttcctttga 2340

gaattgtgcg acttcacaaa atgcaaggtg aacaccactt tgtctctgag aacagacgtt 2400

accaattatg gagtgtcacc agctgccaaa atcgtaggtg ttggctctgc tggtcactgg 2460

agtagttgct actcttcaga atatggacaa agaaggcaca ggtgtaaata tagtagcagg 2520

atgaggaacc tcaaactggg tatcattttg cacgtgctct tctgttctca aatgctaaat 2580

gcaaacactg tgtatttatt agttaggtgt gccaaactac cgttcccaaa ttggtgtttc 2640

tgaatgacat caacattccc ccaacattac tccattacta aagacagaaa aaaataaaaa 2700

cataaaatat acaaacatgt ggcaacctgt tcttcctacc aaatataaac ttgtgtatga 2760

tccaagtatt ttatctgtgt tgtctctcta aacccaaata aatgtgtaaa tgtggacaca 2820

tctc 2824

<210> 3
<211> 1758
<212> DNA
<213> Artificial Sequence

<220>
<223> Optimized human GAD65

<400> 3
atggcatctc cgggctccgg cttttggtcc ttcgggtcgg aagatggctc aggggattcc 60

gagaatcccg gcacagcgcg ggcctggtgt caagtggctc agaagttcac gggcggcatc 120

ggaaacaaac tgtgtgccct gctctacggc gacgccgaga agcccgcaga gagcggcggg 180

agccaacccc cgcgggccgc cgcccggaag gccgcctgcg cctgtgacca gaagccctgc 240

tcatgcagca aggtagatgt caactacgcg tttctccatg ccacagatct gctgccggct 300

tgcgacggtg aaaggcccac tttggccttt ctgcaggatg ttatgaacat tctgctgcag 360

tacgtggtga aaagtttcga ccggtcaacc aaagtgatcg actttcacta tcctaatgaa 420

cttctccagg agtacaattg ggagctggct gaccagccac agaacctgga ggaaatcttg 480

atgcattgcc aaactactct aaaatatgca attaaaacag gccatcctag atacttcaac 540

cagctttcta ccggtttgga tatggtgggg ctggcagccg actggctgac atccaccgca 600

aataccaaca tgttcaccta tgagatcgct cctgtcttcg tgcttttgga atacgtcacc 660

ctaaagaaga tgcgtgaaat cattggctgg ccaggaggct ctggtgatgg tatattttct 720

cccggcggcg cgatctctaa catgtatgcc atgatgatcg cacgctttaa gatgttccca 780

gaagtcaagg agaaaggaat ggctgctctt cccaggctca ttgccttcac gagtgaacac 840

agtcactttt ccctcaagaa gggggctgcc gccttaggga tcggaacaga cagcgtgatt 900

ctgataaagt gcgacgagag agggaaaatg attccatctg atcttgagag aaggattctt 960

gaagccaaac agaaagggtt tgtccctttc ctcgtgagtg ccacagctgg aaccaccgtg 1020

tacggcgcat ttgacccccc cttagctgtc gcggatatat gtaagaagta taagatctgg 1080

atgcacgtgg atgctgcttg gggtggggga ttactgatgt ccaggaaaca caagtggaaa 1140

ctgtctggcg tggagcgcgc caacagcgtg acgtggaatc cacacaaaat gatgggagtc 1200

cctttgcagt gctctgctct cctggttcga gaagagggac tgatgcagaa ttgcaaccaa 1260

atgcatgcct cctacctctt tcagcaggat aaacattatg acctgtctta cgacactggt 1320

gacaaggccc tgcagtgtgg gcgccacgtt gatgtattca agctatggct gatgtggagg 1380

gcaaagggga ctaccggttt tgaagcccat gttgacaaat gtctggagtt ggcagagtat 1440

ttatacaata tcataaaaaa ccgagaagga tatgagatgg tgtttgatgg caagcctcag 1500

cacacaaatg tctgcttctg gtacatccct cccagcctac gtactctgga ggacaacgaa 1560

gagagaatga gtcgcctctc gaaggtggct ccagtgatta aagccagaat gatggagtat 1620

ggaaccacaa tggtcagcta ccaacccttg ggggacaagg taaatttctt ccgcatggtc 1680

atctcaaacc cagcggcaac tcaccaagac attgatttcc tgattgaaga gatcgagcgg 1740

ctcggccagg atctgtga 1758

<210> 4
<211> 594
<212> PRT
<213> Homo sapiens

<400> 4
Met Ala Ser Ser Thr Pro Ser Ser Ser Ala Thr Ser Ser Asn Ala Gly
1 5 10 15

Ala Asp Pro Asn Thr Thr Asn Leu Arg Pro Thr Thr Tyr Asp Thr Trp

20 25 30

Cys Gly Val Ala His Gly Cys Thr Arg Lys Leu Gly Leu Lys Ile Cys
35 40 45

Gly Phe Leu Gln Arg Thr Asn Ser Leu Glu Glu Lys Ser Arg Leu Val
50 55 60

Ser Ala Phe Lys Glu Arg Gln Ser Ser Lys Asn Leu Leu Ser Cys Glu
65 70 75 80

Asn Ser Asp Arg Asp Ala Arg Phe Arg Arg Thr Glu Thr Asp Phe Ser
85 90 95

Asn Leu Phe Ala Arg Asp Leu Leu Pro Ala Lys Asn Gly Glu Glu Gln
100 105 110

Thr Val Gln Phe Leu Leu Glu Val Val Asp Ile Leu Leu Asn Tyr Val
115 120 125

Arg Lys Thr Phe Asp Arg Ser Thr Lys Val Leu Asp Phe His His Pro
130 135 140

His Gln Leu Leu Glu Gly Met Glu Gly Phe Asn Leu Glu Leu Ser Asp
145 150 155 160

His Pro Glu Ser Leu Glu Gln Ile Leu Val Asp Cys Arg Asp Thr Leu
165 170 175

Lys Tyr Gly Val Arg Thr Gly His Pro Arg Phe Phe Asn Gln Leu Ser
180 185 190

Thr Gly Leu Asp Ile Ile Gly Leu Ala Gly Glu Trp Leu Thr Ser Thr
195 200 205

Ala Asn Thr Asn Met Phe Thr Tyr Glu Ile Ala Pro Val Phe Val Leu
210 215 220

Met Glu Gln Ile Thr Leu Lys Lys Met Arg Glu Ile Val Gly Trp Ser
225 230 235 240

Ser Lys Asp Gly Asp Gly Ile Phe Ser Pro Gly Gly Ala Ile Ser Asn
245 250 255

Met Tyr Ser Ile Met Ala Ala Arg Tyr Lys Tyr Phe Pro Glu Val Lys
260 265 270

Thr Lys Gly Met Ala Ala Val Pro Lys Leu Val Leu Phe Thr Ser Glu
275 280 285

Gln Ser His Tyr Ser Ile Lys Lys Ala Gly Ala Ala Leu Gly Phe Gly
290 295 300

Thr Asp Asn Val Ile Leu Ile Lys Cys Asn Glu Arg Gly Lys Ile Ile
305 310 315 320

Pro Ala Asp Phe Glu Ala Lys Ile Leu Glu Ala Lys Gln Lys Gly Tyr
325 330 335

Val Pro Phe Tyr Val Asn Ala Thr Ala Gly Thr Thr Val Tyr Gly Ala
340 345 350

Phe Asp Pro Ile Gln Glu Ile Ala Asp Ile Cys Glu Lys Tyr Asn Leu
355 360 365

Trp Leu His Val Asp Ala Ala Trp Gly Gly Gly Leu Leu Met Ser Arg
370 375 380

Lys His Arg His Lys Leu Asn Gly Ile Glu Arg Ala Asn Ser Val Thr
385 390 395 400

Trp Asn Pro His Lys Met Met Gly Val Leu Leu Gln Cys Ser Ala Ile
405 410 415

Leu Val Lys Glu Lys Gly Ile Leu Gln Gly Cys Asn Gln Met Cys Ala
420 425 430

Gly Tyr Leu Phe Gln Pro Asp Lys Gln Tyr Asp Val Ser Tyr Asp Thr
435 440 445

Gly Asp Lys Ala Ile Gln Cys Gly Arg His Val Asp Ile Phe Lys Phe
450 455 460

Trp Leu Met Trp Lys Ala Lys Gly Thr Val Gly Phe Glu Asn Gln Ile
465 470 475 480

Asn Lys Cys Leu Glu Leu Ala Glu Tyr Leu Tyr Ala Lys Ile Lys Asn
485 490 495

Arg Glu Glu Phe Glu Met Val Phe Asn Gly Glu Pro Glu His Thr Asn
500 505 510

Val Cys Phe Trp Tyr Ile Pro Gln Ser Leu Arg Gly Val Pro Asp Ser
515 520 525

Pro Gln Arg Arg Glu Lys Leu His Lys Val Ala Pro Lys Ile Lys Ala
530 535 540

Leu Met Met Glu Ser Gly Thr Thr Met Val Gly Tyr Gln Pro Gln Gly
545 550 555 560

Asp Lys Ala Asn Phe Phe Arg Met Val Ile Ser Asn Pro Ala Ala Thr
565 570 575

Gln Ser Asp Ile Asp Phe Leu Ile Glu Glu Ile Glu Arg Leu Gly Gln
580 585 590

Asp Leu

<210> 5
<211> 1784
<212> DNA
<213> Homo sapiens

<400> 5
atggcgtctc gaccccatct tcgtccgcaa cctcctcgaa cgcgggagcg gaccccaata 60

ccactaacct gcgccccaca acgtacgata cctggtgcgg cgtggcccat ggatgcacca 120

gaaaactggg gctcaagatc tgcggcttct tgcaaaggac caacagcctg gaagagaaga 180

gtcgccttgt gagtgccttc aaggagaggc aatcctccaa gaacctgctt tcctgtgaaa 240

acagcgaccg ggatgcccgc ttccggcgca cagagactga cttctctaat ctgtttgcta 300

gagatctgct tccggctaag aacggtgagg agcaaaccgt gcaattcctc ctggaagtgg 360

tggacatact cctcaactat gtccgcaaga catttgatcg ctccaccaag gtgctggact 420

ttcatcaccc acaccagttg ctggaaggca tggagggctt caacttggag ctctctgacc 480

accccgagtc cctggagcag atcctggttg actgcagaga caccttgaag tatggggttc 540

gcacaggtca tcctcgattt ttcaaccagc tctccactgg attggatatt attggcctag 600

ctggagaatg gctgacatca acggccaata ccaacatgtt tacatatgaa attgcaccag 660

tgtttgtcct catggaacaa ataacactta agaagatgag agagatagtt ggatggtcaa 720

gtaaagatgg tgatgggata ttttctcctg ggggcgccat atccaacatg tacagcatca 780

tggctgctcg ctacaagtac ttcccggaag ttaagacaaa gggcatggcg gctgtgccta 840

aactggtcct cttcacctca gaacagagtc actattccat aaagaaagct ggggctgcac 900

ttggctttgg aactgacaat gtgattttga taaagtgcaa tgaaaggggg aaaataattc 960

cagctgattt tgaggcaaaa attcttgaag ccaaacagaa gggatatgtt ccctttatg 1020

tcaatgcaac tgctggcacg actgtttatg gagcttttga tccgatacaa gagattgcag 1080

atatatgtga gaaatataac ctttggttgc atgtcgatgc tgcctgggga ggtgggctgc 1140

tcatgtccag gaagcaccgc cataaactca acggcataga aagggccaac tcagtcacct 1200

ggaaccctca caagatgatg ggcgtgctgt tgcagtgctc tgccattctc gtcaaggaaa 1260

agggtatact ccaaggatgc aaccagatgt gtgcaggata cctcttccag ccagacaagc 1320

agtatgatgt ctcctacgac accggggaca aggcaattca gtgtggccgc cacgtggata 1380

tcttcaagtt ctggctgatg tggaaagcaa agggcacagt gggatttgaa aaccagatca 1440

acaaatgcct ggaactggct gaatacctct atgccaagat taaaaacaga gaagaatttg 1500

agatggtttt caatggcgag cctgagcaca caaacgtctg tttttggtat attccacaaa 1560

gcctcagggg tgtgccagac agccctcaac gacgggaaaa gctacacaag gtggctccaa 1620

aaatcaaagc cctgatgatg gagtcaggta cgaccatggt tggctaccag ccccaagggg 1680

acaaggccaa cttcttccgg atggtcatct ccaacccagc cgctacccag tctgacattg 1740

acttcctcat tgaggagata gaaagactgg gccaggatct gtaa 1784

<210> 6
<211> 178
<212> PRT
<213> Rattus norvegicus

<400> 6

Met Pro Gly Ser Ala Leu Leu Cys Cys Leu Leu Leu Leu Ala Gly Val
1 5 10 15

Lys Thr Ser Lys Gly His Ser Ile Arg Gly Asp Asn Asn Cys Thr His
20 25 30

Phe Pro Val Ser Gln Thr His Met Leu Arg Glu Leu Arg Ala Ala Phe
35 40 45

Ser Gln Val Lys Thr Phe Phe Gln Lys Lys Asp Gln Leu Asp Asn Ile
50 55 60

Leu Leu Thr Asp Ser Leu Leu Gln Asp Phe Lys Gly Tyr Leu Gly Cys
65 70 75 80

Gln Ala Leu Ser Glu Met Ile Lys Phe Tyr Leu Val Glu Val Met Pro
85 90 95

Gln Ala Glu Asn His Gly Pro Glu Ile Lys Glu His Leu Asn Ser Leu
100 105 110

Gly Glu Lys Leu Lys Thr Leu Trp Ile Gln Leu Arg Arg Cys His Arg
115 120 125

Phe Leu Pro Cys Glu Asn Lys Ser Lys Ala Val Glu Gln Val Lys Asn
130 135 140

Asp Phe Asn Lys Leu Gln Asp Lys Gly Val Tyr Lys Ala Met Asn Glu
145 150 155 160

Phe Asp Ile Phe Ile Asn Cys Ile Glu Ala Tyr Val Thr Leu Lys Met
165 170 175

Lys Asn

<210> 7
<211> 682
<212> DNA
<213> Rattus norvegicus

<400> 7
catgcctggc tcagcactgc tatgttgcct gctcttactg gctggagtga agaccagcaa 60

aggccattcc atccggggtg acaataactg cacccacttc ccagtcagcc agacccacat 120

gctccgagag ctgagggctg ccttcagtca agtgaagact ttctttcaaa agaaggacca 180

gctggacaac atactgctga cagattcctt actgcaggac tttaagggtt acttgggttg 240

ccaagccttg tcagaaatga tcaagtttta cctggtagaa gtgatgcccc aggcagagaa 300

ccatggccca gaaatcaagg agcatttgaa ttccctggga gagaagctga agaccctctg 360

gatacagctg cgacgctgtc atcgatttct cccctgtgag aataaaagca aggcagtgga 420

gcaggtgaag aatgatttta ataagctcca agacaaaggt gtctacaagg ccatgaatga 480

gtttgacatc ttcatcaact gcatagaagc ctacgtgaca ctcaaaatga aaaattgaac 540

cacccggcat ctactggact gcaggacata aatagagctt ctaaatctga tccagagatc 600

ttagctaacg ggagcaactc cttggaaaac ctcgtttgta cctctctcca aaatatttat 660

tacctctgat acctcagttc cc 682

<210> 8
<211> 537
<212> DNA
<213> Artificial Sequence

<220>
<223> Optimized rat IL-10

<400> 8
atgcctggct cagccctgct atgttgcctt ctcctgctgg cgggagtcaa gacaagcaag 60

ggccattcca tccggggaga taataactgc acccacttcc cagtctctca aacccacatg 120

ttgcgagagc tgagggctgc cttcagtcag gtgaagacgt tcttccagaa gaaggaccag 180

ctggacaaca ttctgctgac tgacagcctg ctgcaggatt tcaagggtta tttggggtgt 240

caagccctgt ctgaaatgat caagttttac ctggtagaag tgatgcccca ggcagagaat 300

catggccccg agatcaagga gcacctcaac tccctggggg agaagctgaa gaccctgtgg 360

attcagctga ggcgctgcca cagatttctc ccctgtgaaa acaagagcaa ggcagtggag 420

caggtgaaga acgattttaa taagctccag gacaagggcg tctacaaggc catgaacgag 480

ttcgacatct ttatcaactg catagaagct tacgttacac tcaagatgaa gaattga 537

<210> 9
<211> 178
<212> PRT
<213> Homo sapiens

<400> 9
Met His Ser Ser Ala Leu Leu Cys Cys Leu Val Leu Leu Thr Gly Val
1 5 10 15

Arg Ala Ser Pro Gly Gln Gly Thr Gln Ser Glu Asn Ser Cys Thr His
20 25 30

Phe Pro Gly Asn Leu Pro Asn Met Leu Arg Asp Leu Arg Asp Ala Phe
35 40 45

Ser Arg Val Lys Thr Phe Phe Gln Met Lys Asp Gln Leu Asp Asn Leu
50 55 60

Leu Leu Lys Glu Ser Leu Leu Glu Asp Phe Lys Gly Tyr Leu Gly Cys
65 70 75 80

Gln Ala Leu Ser Glu Met Ile Gln Phe Tyr Leu Glu Glu Val Met Pro
85 90 95

Gln Ala Glu Asn Gln Asp Pro Asp Ile Lys Ala His Val Asn Ser Leu
100 105 110

Gly Glu Asn Leu Lys Thr Leu Arg Leu Arg Leu Arg Arg Cys His Arg
115 120 125

Phe Leu Pro Cys Glu Asn Lys Ser Lys Ala Val Glu Gln Val Lys Asn

130 135 140

Ala Phe Asn Lys Leu Gln Glu Lys Gly Ile Tyr Lys Ala Met Ser Glu
145 150 155 160

Phe Asp Ile Phe Ile Asn Tyr Ile Glu Ala Tyr Met Thr Met Lys Ile
165 170 175

Arg Asn

<210> 10
<211> 1600
<212> DNA
<213> Homo sapiens

<400> 10
aaaccacaag acagacttgc aaaagaaggc atgcacagct cagcactgct ctgttgcctg 60

gtcctcctga ctggggtgag ggccagccca ggccagggca cccagtctga gaacagctgc 120

acccacttcc caggcaacct gcctaacatg cttcgagatc tccgagatgc cttcagcaga 180

gtgaagactt tctttcaaat gaaggatcag ctggacaact tgttgttaaa ggagtccttg 240

ctggaggact ttaagggtta cctgggttgc caagccttgt ctgagatgat ccagttttac 300

ctggaggagg tgatgcccca agctgagaac caagacccag acatcaaggc gcatgtgaac 360

tccctggggg agaacctgaa gaccctcagg ctgaggctac ggcgctgtca tcgatttctt 420

ccctgtgaaa acaagagcaa ggccgtggag caggtgaaga atgcctttaa taagctccaa 480

gagaaaggca tctacaaagc catgagtgag tttgacatct tcatcaacta catagaagcc 540

tacatgacaa tgaagatacg aaactgagac atcagggtgg cgactctata gactctagga 600

cataaattag aggtctccaa aatcggatct ggggctctgg gatagctgac ccagcccctt 660

gagaaacctt attgtacctc tcttatagaa tatttattac ctctgatacc tcaacccccа 720

tttctattta tttactgagc ttctctgtga acgatttaga aagaagccca atattataat 780

ttttttcaat atttattatt ttcacctgtt tttaagctgt ttccataggg tgacacacta 840

tggtatttga gtgttttaag ataaattata agttacataa gggaggaaaa aaaatgttct 900

ttggggagcc aacagaagct tccattccaa gcctgaccac gctttctagc tgttgagctg 960

ttttccctga cctccctcta atttatcttg tctctgggct tggggcttcc taactgctac 1020

aaatactctt aggaagagaa accagggagc ccctttgatg attaattcac cttccagtgt 1080

ctcggaggga ttcccctaac ctcattcccc aaccacttca ttcttgaaag ctgtggccag 1140

cttgttattt ataacaacct aaatttggtt ctaggccggg cgcggtggct cacgcctgta 1200

atcccagcac tttgggaggc tgaggcgggt ggatcacttg aggtcaggag ttcctaacca 1260

gcctggtcaa catggtgaaa ccccgtctct actaaaaata caaaaattag ccgggcatgg 1320

tggcgcgcac ctgtaatccc agctacttgg gaggctgagg caagagaatt gcttgaaccc 1380

aggagatgga agttgcagtg agctgatatc atgcccctgt actccagcct gggtgacaga 1440

gcaagactct gtctcaaaaa ataaaaataa aaataaattt ggttctaata gaactcagtt 1500

ttaactagaa tttattcaat tcctctggga atgttacatt gtttgtctgt cttcatagca 1560

gattttaatt ttgaataaat aaatgtatct tattcacatc 1600

<210> 11
<211> 147
<212> PRT
<213> Rattus norvegicus

<400> 11

Met Gly Leu Ser Pro His Leu Ala Val Thr Leu Phe Cys Phe Leu Ile
1 5 10 15

Cys Thr Gly Asn Gly Ile His Gly Cys Asn Asp Ser Pro Leu Arg Glu
20 25 30

Ile Ile Asn Thr Leu Asn Gln Val Thr Glu Lys Gly Thr Pro Cys Thr
35 40 45

Glu Met Phe Val Pro Asp Val Leu Thr Ala Thr Arg Asn Thr Thr Glu
50 55 60

Asn Glu Leu Ile Cys Arg Ala Ser Arg Val Leu Arg Lys Phe Tyr Phe
65 70 75 80

Pro Arg Asp Val Pro Pro Cys Leu Lys Asn Lys Ser Gly Val Leu Gly
85 90 95

Glu Leu Arg Lys Leu Cys Arg Gly Val Ser Gly Leu Asn Ser Leu Arg
100 105 110

Ser Cys Thr Val Asn Glu Ser Thr Leu Thr Thr Leu Lys Asp Phe Leu
115 120 125

Glu Ser Leu Lys Ser Ile Leu Arg Gly Lys Tyr Leu Gln Ser Cys Thr
130 135 140

Ser Met Ser
145

<210> 12
<211> 475
<212> DNA
<213> Rattus norvegicus

<400> 12
tctcacgtca ctgactgtag agagctattg atgggtctca gcccccacct tgctgtcacc 60

ctgttctgct ttctcatatg taccgggaac ggtatccacg gatgtaacga cagccctctg 120

agagagatca tcaacacttt gaaccaggtc acagaaaaag ggactccatg caccgagatg 180

tttgtaccag acgtccttac ggcaacaagg aacaccacgg agaacgagct catctgcagg 240

gcttccaggg tgcttcgcaa attttacttc ccacgtgatg tacctccgtg cttgaagaac 300

aagtctgggg ttctcggtga actgaggaaa ctctgtagag gtgtcagcgg tctgaactca 360

ctgagaagct gcaccgtgaa tgagtccacg ctcacaacac tgaaagactt cctggaaagc 420

ctaaaaagca tcctacgagg gaaatacttg cagtcctgca cttccatgtc ctaac 475

<210> 13
<211> 444
<212> DNA
<213> Artificial Sequence

<220>
<223> Optimized rat IL-4

<400> 13
atgggtttaa gcccccacct gccgtcaca ctgttctgtt ttctcatctg taccgggaac 60

ggaattcatg gctgtaacga cagccctctg agagagatta tcaacacctt gaatcaggtt 120

accgaaaaag gcactccatg caccgagatg tttgtaccag atgtgcttac ggcaacgagg 180

aacaccactg agaatgagct gatctgtcgg gcttctcgag tgctgcgcaa attctacttc 240

cctcgtgatg tgcccccgtg cttgaagaac aagtcaggcg tgctcggaga actgaggaag 300

ctctgcagag gcgtctcagg gctgaattct ctgcgcagct gcaccgtgaa tgaatccaca 360

ctcacaaccc tgaaagactt cctggagagc ctgaagagca tcctacgggg gaagtatctc 420

cagtcctgca cttccatgag ttga 444

<210> 14
<211> 153
<212> PRT
<213> Homo sapiens

<400> 14
Met Gly Leu Thr Ser Gln Leu Leu Pro Pro Leu Phe Phe Leu Leu Ala
1 5 10 15

Cys Ala Gly Asn Phe Val His Gly His Lys Cys Asp Ile Thr Leu Gln
20 25 30

Glu Ile Ile Lys Thr Leu Asn Ser Leu Thr Glu Gln Lys Thr Leu Cys
35 40 45

Thr Glu Leu Thr Val Thr Asp Ile Phe Ala Ala Ser Lys Asn Thr Thr
50 55 60

Glu Lys Glu Thr Phe Cys Arg Ala Ala Thr Val Leu Arg Gln Phe Tyr
65 70 75 80

Ser His His Glu Lys Asp Thr Arg Cys Leu Gly Ala Thr Ala Gln Gln
85 90 95

Phe His Arg His Lys Gln Leu Ile Arg Phe Leu Lys Arg Leu Asp Arg
100 105 110

Asn Leu Trp Gly Leu Ala Gly Leu Asn Ser Cys Pro Val Lys Glu Ala
115 120 125

Asn Gln Ser Thr Leu Glu Asn Phe Leu Glu Arg Leu Lys Thr Ile Met
130 135 140

Arg Glu Lys Tyr Ser Lys Cys Ser Ser
145 150

<210> 15
<211> 642
<212> DNA
<213> Homo sapiens

<400> 15
tgcatcgtta gcttctcctg ataaactaat tgcctcacat tgtcactgca aatcgacacc 60

tattaatggg tctcacctcc caactgcttc cccctctgtt cttcctgcta gcatgtgccg 120

gcaactttgt ccacggacac aagtgcgata tcaccttaca ggagatcatc aaaactttga 180

acagcctcac agagcagaag actctgtgca ccgagttgac cgtaacagac atctttgctg 240

cctccaagaa cacaactgag aaggaaacct tctgcagggc tgcgactgtg ctccggcagt 300

tctacagcca ccatgagaag gacactcgct gcctgggtgc gactgcacag cagttccaca 360

ggcacaagca gctgatccga ttcctgaaac ggctcgacag gaacctctgg ggcctggcgg 420

gcttgaattc ctgtcctgtg aaggaagcca accagagtac gttggaaaac ttcttggaaa 480

ggctaaagac gatcatgaga gagaaatatt caaagtgttc gagctgaata ttttaattta 540

tgagtttttg atagctttat tttttaagta tttatatatt tataactcat cataaaataa 600

agtatatata gaatctaaaa aaaaaaaaaa aaaaaaaaaa aa 642

<210> 16
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward primer for amplifying CMV promoter

<400> 16
ttcggccgtc gaggagcttg gcccattg 28

<210> 17
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse primer for amplifying CMV promoter

<400> 17
gacgtcgacc tagctagcga attcggggcc gcggag 36

<210> 18
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward primer for amplifying SV40pA

<400> 18
ccatcgatca gacatgataa gatacattga tgag 34

<210> 19
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse primer for amplifying SV40pA

<400> 19
gacgtcgacg cggccgctac cacatttgta gaggttttac ttg 43

<210> 20
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward primer for amplifying Kanamycin resistant gene

<400> 20
aggcgccatgagccatattcaacgggaa 28

<210> 21
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse primer for amplifying Kanamycin resistant gene

<400> 21
ttcatgatta gaaaaactca tcgagcatc 29

<210> 22
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward primer for amplifying LITR and CMV

<400> 22
atggcgcgcc cctggccttt tgctggcc 28

<210> 23
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse primer for amplifying SV40pA and RITR

<400> 23
atggatccgc tagtaaatac cgcatcag 28

<210> 24
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward primer for amplifying rIL-10

<400> 24
ccgctagcgc caccatgcct 20

<210> 25
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse primer for amplifying rIL-10

<400> 25
gacgtcgacg ccatcgatgg cttaattaat caattcttc 39

Claims:

Claim 1. Use of a composition comprising a gene encoding glutamate decarboxylase (GAD) and a gene encoding interleukin-10 (IL-10) in the manufacture of a medicament for relieving or treating pain, wherein the pain is nociceptive pain, inflammatory pain, or pathological pain.

Claim 2. The use according to claim 1, wherein the composition comprises a first vector operably containing a gene encoding GAD and a second vector operably containing a gene encoding IL-10.

Claim 3. The use according to claim 2, wherein the composition comprises a first vector containing a gene encoding GAD and a second vector containing a gene encoding IL-10 in a virus titer-based mixing ratio per unit volume of 1: 1 to 1: 50.

Claim 4. The use according to claim 3, wherein the first vector and the second vector comprise at least one viral vector selected from the group consisting of adenovirus, adeno-associated virus, herpes simplex virus, lentivirus, retrovirus and poxvirus.

Claim 5. The use according to any preceding claim, wherein the GAD is at least one selected from the group consisting of GAD65 and GAD67.

Claim 6. The use according to claim 5, wherein the GAD consists of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 4.

Claim 7. The use according to claim 5, wherein the gene encoding GAD consists of the base sequence of SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 5.

Claim 8. The use according to any preceding claim, wherein the IL-10 consists of the amino acid sequence of SEQ ID NO: 6 or SEQ ID NO: 9.

Claim 9. The use according to any of claims 1 to 7, wherein the gene encoding IL-10 consists of the base sequence of SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 10.

Claim 10. The use according to any preceding claim, wherein the pain is neuropathic pain, cancer pain, postoperative pain, trigeminal neuralgia, idiopathic pain, diabetic neuropathic pain, or migraine.

Claim 11. The use according to claim 1, wherein the pharmaceutical composition further comprises a physiologically acceptable carrier.

Claim 12. The use according to any preceding claim, wherein the pharmaceutical composition is provided in the form of an injection.

[Fig. 1]



[Fig. 2]



[Fig. 3]



[Fig. 4]


AAV5-GAD65
Cell only
AAV1-IL10
Cell only
AAV1-IL4
Cell only
*
*
*
GAD65
(65 KDa)
IL-10
(20 KDa)
IL-4
(18 KDa)

[Fig. 5]


GABA (ng/ml)
2500
2000
1500
1000
500
0
untreated cell
AAV5-hGAD65-treated cell

[Fig. 6]


Paw Withdrawal threshold(g)
8
6
4
2
0
*
Negative Control
Gabapentin 30mg/kg
GAD65+IL-10
Mean±S.E.M. *P<0.05

[Fig. 7]


Paw Withdrawal Threshold (g)
12
10
8
6
4
2
0
*
*
*
Negative Ctrl
GAD
IL-10
GAD +IL-10 (1:1)
GAD +IL-10 (1:5)
GAD +IL-10 (1:30)
Mean±S.E.M. *P<0.05

[Fig. 8]


Paw Withdrawal Threshold (g)
8
6
4
2
0
GAD65+IL-10 (1:10)
GAD65+IL-10 (1:30)

[Fig. 9]


AUC (arbitrary units²)
50
40
30
20
10
0
*
*
*
*
*
Negative Control
GAD
IL-4
IL-10
GAD + IL-4
GAD + IL-10
*P<0.05